Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, reported first quarter 2018 net profit of Dh18.4 million and sales of Dh264.0 million, after implementation of new Accounting Standard IFRS 9 and IFRS 15.

Julphar’s results were announced at a Board of Directors’ meeting, which was chaired by Shaikh Faisal Bin Saqr Al Qasimi, Chairman of the Board of Julphar. Commenting on the announcement, Jerome Carle, General Manager of Julphar, said: “In the first three months of 2018, we made significant progress in UAE and Levant and we resumed our operations in Libya. This is a good set of results showing the progress we are making.”